Financials

People

Activity

Alzheimer's Drug Discovery Foundation

Company

Investment-firm

Financing round

General

About Company
The Alzheimer’s Drug Discovery Foundation finds drugs for Alzheimer’s disease.

Industry

Sector :

Subsector :

Also Known As

ADDF

founded date

01.01.1998

Number of employees

Company Type

For Profit

IPO status

Private

Description

The Alzheimer’s Drug Discovery Foundation is a public charity that focuses on discovering effective drugs for Alzheimer’s disease. They use a biomedical venture philanthropy approach to invest in promising drug discovery and development programs worldwide. Since their establishment in 1998, they have invested nearly $100 million to support over 500 programs in 18 countries. Their mission is to accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
ReceptorPharma

ReceptorPharma

ReceptorPharma is a drug discovery company revolutionizing Alzheimer's disease treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Lund, Sweden

total rounds

1
Sequence Bio

Sequence Bio

The company aims to improve drug target discovery and treatment of diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

St. John's, NL, Canada

total rounds

5
AI for ALS

AI for ALS

Provider of in silico drug discovery and drug repurposing for age-related diseases

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Baltimore, MD, USA
Perlara

Perlara

Perlara, PBC is a precision drug discovery company that accelerates the discovery of drugs for rare genetic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

6

total raised

$11.76M

Financials

Investments
34
Date 
name 
Lead 
type 
Raised 
26.07.2024
No
$10M
07.03.2024
Yes
$250K
RetiSpec

RetiSpec

RetiSpec is a medical imaging startup developing an eye scanner for early detection of Alzheimer's Disease pathology.

Sector

Electronic and Electrical Equipment

Subsector

Gauges and Meters

Keywords

Health Care, Machine Learning, Artificial Intelligence

Location

Toronto, ON, Canada

total rounds

6

total raised

$10.75M
Coya Therapeutics

Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company developing treatments for inflammation and neuroinflammation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Houston, TX, USA

total rounds

4

total raised

$51.8M
NeuroAge Therapeutics

NeuroAge Therapeutics

NeuroAge Therapeutics is a longevity biotech firm that develops new medications to regenerate biological brain aging.

total rounds

3

total raised

$425K
Co-Investors
Exits
1
Tetra Therapeutics

Tetra Therapeutics

Tetra Discovery Partners develops drugs for brain-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Grand Rapids, MI, USA

total rounds

1

total raised

$5M

People

Founders
2
Leonard Lauder
Leonard Lauder

Leonard Lauder

Leonard A. Lauder is Chairman Emeritus of The Estée Lauder Companies Inc. and is currently the senior member of its Board of Directors. Founded in 1946, the Company is one of the world's leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products, with annual sales of $10.97 billion. Its products are sold in over 150 countries and territories across more than 30 well-recognized brand names. A graduate of the University of Pennsylvania’s Wharton School, Mr. Lauder also studied at Columbia University’s Graduate School of Business and served as a lieutenant in the U.S. Navy. He formally joined Estée Lauder in 1958, when it had annual sales of $800,000. Mr. Lauder consistently developed and implemented innovative sales and marketing programs and increased the Company’s sales and profits. He created its first research and development laboratory and brought in professional management on every level. He also initiated The Estée Lauder Companies’ international expansion, which began in 1960 with the opening of the Estée Lauder account at Harrods in London. Mr. Lauder served as President of The Estée Lauder Companies from 1972 to 1995 and as Chief Executive Officer from 1982 to 1999. He added the title of Chairman in 1995 and served as Chairman of The Estée Lauder Companies through June 2009. Under his leadership, the Company launched many brands, including Aramis, Clinique, Lab Series and Origins. Beginning in the mid-1990s, the company also began expanding through acquisitions, including Aveda, Bobbi Brown, Jo Malone London, La Mer and M·A·C. In addition to his activities with The Estée Lauder Companies, Mr. Lauder is extremely involved in the worlds of education, art, politics and philanthropy. He is Emeritus Trustee of the University of Pennsylvania and a founding member of the Board of Governors of its Joseph H. Lauder Institute of Management and International Studies. Mr. Lauder became a Trustee of the Whitney Museum of American Art in New York City in 1977 and currently serves as its Chairman Emeritus. He is Co-Founder and Co-Chairman of the Alzheimer’s Drug Discovery Foundation; Co-Chairman of the Breast Cancer Research Foundation Board of Directors; a member of the Council on Foreign Relations; Chairman Emeritus and Lifetime Trustee of the Board of Directors of the Aspen Institute, as well as former Chairman of the Aspen Institute International Committee; and a member of the President’s Council of Memorial Sloan-Kettering Hospital. Mr. Lauder served on the Advisory Committee for Trade Negotiations under President Ronald Reagan. Among his honors, he has been named an Officier de la Légion d’Honneur by France and recognized by the United States Navy Supply Corps Foundation with its Distinguished Alumni Award. The Lauder Family received the esteemed 2011 Carnegie Medal of Philanthropy in recognition of its long-standing commitment to philanthropy and public service. Mr. Lauder was the 2013 recipient of the Palazzo Strozzi Renaissance Man of the Year Award, and most recently, he was named a 2014 Living Landmark by the New York Landmarks Conservancy. Mr. Lauder was married to Evelyn H. Lauder (Senior Corporate Vice President for The Estée Lauder Companies Inc.) from 1959 until she passed away in 2011. They had two sons together, William (Executive Chairman, The Estée Lauder Companies) and Gary (Managing Partner, Lauder Partners LLC), and five grandchildren. On January 1, 2015, Mr. Lauder married Judy Glickman Lauder, an internationally recognized philanthropist and photographer whose work is represented in over 300 public and private collections, including the J. Paul Getty Museum and the Whitney Museum of American Art.

current job

Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation

organization founded

1

Leonard Lauder

Ronald S. Lauder

current job

Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation

organization founded

1

Ronald S. Lauder

Employee Profiles
23

Nicholas Mckeehan

Assistant director, aging and alzheimer's prevention

Melanie Beczak

Associate director of database and operations

Sumy Cho

Digital media manager

Stephen Toma

Member of the board of overseers

Giorgio Zeolla

Director of major gifts

Jessica Levine

Graphic designer

Martin Tolar

Martin Tolar

Business Advisory Board & Scientific Review Board

Howard Fillit

Howard Fillit

Founding Executive Director and Chief Science Officer

Activity

Recent News
11
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month